Super-dose anti-VEGF (SAVE) trial: 2.0 mg Intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'Super-dose anti-VEGF (SAVE) trial: 2.0 mg Intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point'. Together they form a unique fingerprint.

Medicine & Life Sciences